Luminespib
Product Specifications
UNSPSC Description
Luminespib (VER-52296) is a potent HSP90 inhibitor with IC50s of 7.8 and 21 nM for HSP90α and HSP90β, respectively[1].
Target Antigen
Apoptosis; Autophagy; HSP
Type
Reference compound
Related Pathways
Apoptosis;Autophagy;Cell Cycle/DNA Damage;Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/NVP-AUY922.html
Purity
99.89
Solubility
DMSO : ≥ 62 mg/mL
Smiles
O=C(C1=NOC(C2=CC(C(C)C)=C(O)C=C2O)=C1C3=CC=C(CN4CCOCC4)C=C3)NCC
Molecular Weight
465.54
References & Citations
[1]Eccles, Suzanne A., et al. NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis. Cancer Research (2008), 68(8), 2850-2860.|[2]Best OG, et al. Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with NSC 118218 against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype. Leuk Lymphoma. 2012 Jul 9.|[3]Moser C, et al. Stoeltzing O.Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res. 2012 Jul;32(7):2551-61.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-10215/Luminespib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-10215/Luminespib-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
747412-49-3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6279129-01 0.1 mL
BTBD17, CT (BTBD17, BTB/POZ domain-containing protein 17, Galectin-3-binding protein-like) (MaxLight 650)
Ask
View Details MBS6279129-02 5x 0.1 mL
BTBD17, CT (BTBD17, BTB/POZ domain-containing protein 17, Galectin-3-binding protein-like) (MaxLight 650)
Ask
View Details